Company profile
AURA BIOSCIENCES, INC.
NASDAQ:AURABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BELZUPACAP SAROTALOCAN | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05483868 | phase1 | active_not_recruiting | 2022-09-26 | 2027-03-01 | Aura Biosciences | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer |
| NCT06007690 | phase3 | active_not_recruiting | 2023-12-06 | 2027-11-15 | Aura Biosciences | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma |
| NCT04417530 | phase2 | completed | 2020-08-05 | 2024-04-22 | Aura Biosciences | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma |
| NCT03052127 | phase1_2 | completed | 2017-02-27 | 2021-01-26 | Aura Biosciences | Study in Subjects With Small Primary Choroidal Melanoma |
| NCT06643884 | phase2 | recruiting | 2024-12-16 | 2026-11-30 | Aura Biosciences | Suprachoroidal Administration in Subjects With Metastases to the Choroid |
FDA applications (0)
No records yet.